- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00867087
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
30 oktober 2017 bijgewerkt door: Pfizer
An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation
The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
64
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Berlin, Duitsland, 13353
- Charite Campus Virchow-Kilinikum-
-
-
-
-
-
Lille, Frankrijk, 59037
- Chru de Lille Hopital Claude Huriez
-
Marseille, Frankrijk, 13273
- Institut Paoli Calmettes
-
Montpellier Cedex 5, Frankrijk, 34295
- CHU Saint-Eloi
-
Paris, Frankrijk, 75010
- Hopital Saint Louis
-
Pessac, Frankrijk, 33604
- Hôpital Haut-Lévêque
-
Pierre-Benite cedex 114, Frankrijk, 69495
- CH Lyon sud
-
Pierre-benite Cedex, Frankrijk, 69495
- CH Lyon sud
-
Strasbourg, Frankrijk, 67098
- Departement d'Hematologie et d'Oncologie-
-
-
-
-
-
Seoul, Korea, republiek van, 120-752
- Severance Hospital, Yonsei University Health System
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Korea, republiek van, 135-710
- Samsung Medical Center
-
-
Seoul/korea
-
Seoul, Seoul/korea, Korea, republiek van, 138-736
- Asan Medical Center
-
-
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
-
-
-
-
Manchester, Verenigd Koninkrijk, M20 4BX
- The Christie NHS Foundation Trust
-
Manchester, Verenigd Koninkrijk, M20 4BX
- Christie Hospital
-
-
-
-
Illinois
-
Maywood, Illinois, Verenigde Staten, 60153
- Loyola University Medical Center, Foster G. McGraw Hospital and Satellites
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
Saint Louis, Missouri, Verenigde Staten, 63110-1094
- Barnes-Jewish Hospital
-
Saint Peters, Missouri, Verenigde Staten, 63376
- Siteman Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Hackensack University Medical Center
-
Hackensack, New Jersey, Verenigde Staten, 07601
- John Theurer Cancer Center, Hackensack University Medical Center
-
Hackensack, New Jersey, Verenigde Staten, 07601-1941
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
Hackensack, New Jersey, Verenigde Staten, 07601-2105
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
Hackensack, New Jersey, Verenigde Staten, 07601
- John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC)
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan - Kettering Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033-0850
- Penn State Milton S Hershey Medical Center
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern Medical Center
-
Dallas, Texas, Verenigde Staten, 75235
- Zale Lipshy University Hospital
-
Dallas, Texas, Verenigde Staten, 75235
- UT Southwestern University Hospital - St. Paul
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas, MD Anderson Cancer Center
-
Houston, Texas, Verenigde Staten, 77030-4009
- The University of Texas, M. D. Anderson Cancer Center
-
San Antonio, Texas, Verenigde Staten, 78229
- Methodist Healthcare System of
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792-0001
- University of Wisconsin Hospital and Clinics
-
Madison, Wisconsin, Verenigde Staten, 53792
- Pharmaceutical Research Center
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy
- Relapsed/disease progression within 12 months after start of prior therapy and/or secondary International Prognostic Index (sIPI) score greater than 1
- Eligible for autologous stem cell transplant (aSCT)
Exclusion Criteria:
- Prior allogeneic hematopoietic stem cell transplant
- Within 6 months prior to test article: autologous transplant, treatment with anti-CD22 antibodies, radio-immunotherapy
- Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease, systemic vasculitides, current or chronic hepatitis B or C infection
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2
Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
|
1.8 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
Andere namen:
375 mg/m^2 two days before cycle 1 by intravenous infusion; 375 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Tijdsspanne: Up to 2 years (9 weeks of 3 21-day cycles and every 3 to 6 months during the long-term follow-up period)
|
Response criteria based on National Cancer Institute (NCI) International Response Criteria for non-Hodgkin's lymphoma.
CR: no detectable clinical & radiographic evidence of disease/disease-related symptoms; lymph nodes/nodal masses regressed to normal size (less than or equal to [≤] 1.5 cm in greatest transverse diameter for nodes greater than [>] 1.5 cm pre-therapy); spleen & other organs (if enlarged pre-therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
PR: > or equal to (≥) 50% decrease in sum of product diameters (SPD) of 6 largest dominant nodes/nodal masses; no increase in size of other nodes, liver, or spleen; splenic & hepatic nodules regressed by ≥ 50% in SPD; involvement of other organs usually assessable & no measurable disease present; no new sites of disease.
Participants achieving CR, but with persistent morphologic bone marrow involvement or no bone marrow assessment after treatment were partial responders.
|
Up to 2 years (9 weeks of 3 21-day cycles and every 3 to 6 months during the long-term follow-up period)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Kaplan-Meier Estimate of Progression Free Survival (PFS) 6 Months After Inotuzumab Ozogamicin Plus Rituximab Therapy
Tijdsspanne: 6 months after the first dose of inotuzumab ozogamicin
|
PFS; time from date of randomization to earliest date of progression, relapse after CR, death from any cause without progression, start of new treatment for the lymphoma excluding treatments/procedures for consolidation therapy in this protocol, or censored at date of last tumor assessment.
Progression: abnormal lymph nodes (long axis > 1.5 cm or long axis 1.1 to 1.5 cm and short axis > 1.0 cm); appearance of any new lesion > 1.5 cm in any axis during or at end of treatment; ≥ 50% increase from nadir in SPD of any previously involved nodes, in a single involved node, or in the size of other lesions; ≥ 50% increase in longest diameter of any single previously identified node > 1.0 cm in short axis.
|
6 months after the first dose of inotuzumab ozogamicin
|
Kaplan-Meier Estimate of PFS 2 Years After Inotuzumab Ozogamicin Plus Rituximab Therapy
Tijdsspanne: 2 years after the first dose of inotuzumab ozogamicin
|
PFS; time from date of randomization to earliest date of progression, relapse after CR, death from any cause without progression, start of new treatment for the lymphoma excluding treatments/procedures for consolidation therapy in this protocol, or censored at date of last tumor assessment.
Progression: abnormal lymph nodes (long axis > 1.5 cm or long axis 1.1 to 1.5 cm and short axis > 1.0 cm); appearance of any new lesion > 1.5 cm in any axis during or at end of treatment; ≥ 50% increase from nadir in SPD of any previously involved nodes, in a single involved node, or in the size of other lesions; ≥ 50% increase in longest diameter of any single previously identified node > 1.0 cm in short axis.
|
2 years after the first dose of inotuzumab ozogamicin
|
Percentage of Participants With a Response of CR or PR and Who Had Successful Granulocyte Colony Stimulating Factor (G-CSF) Mobilization of Peripheral Blood Stem Cells (PBSCs) Overall and After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Tijdsspanne: From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks) and up to approximately 2 to 3 weeks after 6 cycles (up to 21 weeks).
|
Successful mobilization of PBSC: ≥ 2 x 10^6 cluster of differentiation (CD) 34+ cells per kilogram (cells/kg) after 3 cycles.
CR: no detectable clinical & radiographic evidence of disease/disease-related symptoms; lymph nodes/nodal masses regressed to normal size (≤ 1.5 cm in greatest transverse diameter for nodes > 1.5 cm pre-therapy); spleen & other organs (if enlarged pre-therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
PR: ≥ 50% decrease in SPD of 6 largest dominant nodes/nodal masses; no increase in size of other nodes, liver, or spleen; splenic & hepatic nodules regressed by ≥ 50% in SPD; involvement of other organs usually assessable & no measurable disease present; no new sites of disease.
Participants achieving CR, but with persistent morphologic bone marrow involvement or no bone marrow assessment post treatment were partial responders.
Response includes confirmed CR/PR and unconfirmed CR/PR.
|
From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks) and up to approximately 2 to 3 weeks after 6 cycles (up to 21 weeks).
|
Percentage of Participants With Successful G-CSF Mobilization of PBSC
Tijdsspanne: From the first dose to approximately 2 to 3 weeks after up to 6 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 21 weeks).
|
Successful mobilization of PBSC was defined as ≥ 2 x 10^6 CD34+ cells/kg collected after 3 cycles of inotuzumab ozogamicin plus rituximab therapy.
|
From the first dose to approximately 2 to 3 weeks after up to 6 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 21 weeks).
|
Percentage of Participants Who Underwent Autologous Stem Cell Transplant (aSCT)
Tijdsspanne: A minimum of 4 weeks and a maximum of 8 weeks after the last cycle of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 26 weeks).
|
Participants underwent high dose chemotherapy and aSCT.
In order to proceed to aSCT, participants were required to achieve CR or PR and successful collection of PSBC (≥ 2.0 x 10^6 CD34+ cells/kg collected after 3 cycles).
|
A minimum of 4 weeks and a maximum of 8 weeks after the last cycle of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 26 weeks).
|
Event-Free Survival (EFS) After aSCT
Tijdsspanne: From the completion of aSCT through 2 year long-term follow-up period, including but not limited to planned assessments scheduled every 3 to 6 months.
|
EFS was the time (in months) from the date of aSCT to the earliest date of progression, relapse after CR, death from any cause without progression, initiation of a new treatment for the lymphoma or was censored at the date of the last tumor assessment.
|
From the completion of aSCT through 2 year long-term follow-up period, including but not limited to planned assessments scheduled every 3 to 6 months.
|
Percentage of Participants With a CR After 3 Cycles of Inotuzumab Ozogamicin Plus Rituximab Therapy
Tijdsspanne: From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks).
|
CR: complete disappearance of all detectable clinical & radiographic evidence of disease & disease-related symptoms; lymph nodes & nodal masses regressed to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy); spleen and other organs (if enlarged prior to therapy) regressed in size & spleen not palpable on physical examination; repeat bone marrow infiltrate clear.
Response includes confirmed CR and unconfirmed CR.
|
From the first dose to approximately 2 to 3 weeks after 3 cycles of inotuzumab ozogamicin plus rituximab (induction) therapy (up to 12 weeks).
|
Overall Survival (OS)
Tijdsspanne: From randomization until the date of death, or the date of last contact if no death occurred (up to 2 years).
|
OS was the time (in months) from the date of randomization to the date of death, and censored at the date of last contact if no death occurred.
|
From randomization until the date of death, or the date of last contact if no death occurred (up to 2 years).
|
Percentage of Participants With Any Grade 3/4 Laboratory Abnormality During Therapy
Tijdsspanne: Within 3 days prior each dose of test article, on Day -2, 1, 8, and 15 of Cycles 1 to 3, 2 to 3 weeks after Cycle 3, at the end-of-treatment visit, and every 3 to 6 months during long-term follow-up (up to 2 years).
|
The following parameters were analyzed for serum chemistry; blood urea nitrogen (or urea), creatinine, glucose, calcium, sodium, potassium, phosphorus, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, total bilirubin (and direct bilirubin, if total bilirubin was elevated), alkaline phosphatase, uric acid (or urate), albumin and total protein.
The following parameters were analyzed for hematology; lymphocytes, basophils, eosinophils, erythrocytes, hematocrit, hemoglobin, leukocytes, monocytes, neutrophils, platelets, prothrombin international normalized ratio, prothrombin time, fibrinogen, and activated partial thromboplastin time.
Laboratory test results were graded using the NCI Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE v3.0).
|
Within 3 days prior each dose of test article, on Day -2, 1, 8, and 15 of Cycles 1 to 3, 2 to 3 weeks after Cycle 3, at the end-of-treatment visit, and every 3 to 6 months during long-term follow-up (up to 2 years).
|
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) During Inotuzumab Ozogamicin Plus Rituximab Treatment
Tijdsspanne: Treatment emergent AEs were collected from time of first dose to end of trial visit (participants not undergoing consolidation treatment) or until consolidation therapy. SAEs were collected from informed consent until end of trial visit (up to 6 months).
|
An AE was any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory/physiologic observations occurring in a participant given a test article or in a clinical study; the event may not necessarily have had a causal relationship with the treatment.
A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; cancer.
Treatment-emergent AEs were AEs that emerged after the first dose of the study treatment during the treatment period that were absent pre-treatment, or worsened during the treatment period relative to the pre-treatment state.
The severity of all AEs was graded by the investigator using the NCI Common Terminology Criteria for AE Version 3.0 (CTCAE v3.0).
|
Treatment emergent AEs were collected from time of first dose to end of trial visit (participants not undergoing consolidation treatment) or until consolidation therapy. SAEs were collected from informed consent until end of trial visit (up to 6 months).
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Medewerkers
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
8 juni 2009
Primaire voltooiing (Werkelijk)
31 oktober 2012
Studie voltooiing (Werkelijk)
31 oktober 2012
Studieregistratiedata
Eerst ingediend
20 maart 2009
Eerst ingediend dat voldeed aan de QC-criteria
20 maart 2009
Eerst geplaatst (Schatting)
23 maart 2009
Updates van studierecords
Laatste update geplaatst (Werkelijk)
5 december 2017
Laatste update ingediend die voldeed aan QC-criteria
30 oktober 2017
Laatst geverifieerd
1 oktober 2017
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het immuunsysteem
- Neoplasmata per histologisch type
- Neoplasmata
- Lymfoproliferatieve aandoeningen
- Lymfatische ziekten
- Immunoproliferatieve aandoeningen
- Lymfoom, non-Hodgkin
- Lymfoom
- Lymfoom, B-cel
- Fysiologische effecten van medicijnen
- Antireumatische middelen
- Antineoplastische middelen
- Immunologische factoren
- Antineoplastische middelen, immunologisch
- Antibiotica, antineoplastiek
- Rituximab
- Inotuzumab Ozogamicin
Andere studie-ID-nummers
- 3129K5-2005
- B1931001 (Andere identificatie: Alias Study Number)
- 2008-007802-12 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Lymfoom, B-cel
-
Peking University People's HospitalOnbekendNatural Killer Cell-gemedieerde immuniteitChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); NovartisActief, niet wervendRefractaire Hurthle Cell-schildklierkankerVerenigde Staten
-
Hadassah Medical OrganizationOnbekendNatural Killer Cell-deficiëntie, familiaal geïsoleerdIsraël
-
Assistance Publique - Hôpitaux de ParisNog niet aan het werven
-
Bing HanVoltooidPure Red Cell Aplasia, verworvenChina
-
Peking University First HospitalWervingNiercelcarcinoom, Clear Cell, SomatischChina
-
National Institute of Diabetes and Digestive and...WervingSchildklierkanker | Papillaire schildklierkanker | Hurthle Cell-schildklierkanker | Tall Cell Variant Schildklierkanker | Folliculaire schildklierkankerVerenigde Staten
-
ExelixisVoltooidNiercelcarcinoom | Papillaire schildklierkanker | Folliculaire schildklierkanker | Huerthle Cell-schildklierkankerVerenigde Staten
-
Jeadran N. Malagón-RojasNog niet aan het wervenStress, psychisch | Ongerustheid | Blootstelling aan het milieu | Cortisol-overschot | Epigenetische stoornis | Natural Killer Cell Cytokine-productieColombia
-
Masonic Cancer Center, University of MinnesotaBeëindigdFolliculair lymfoom | Myelodysplastische syndromen | Multipel myeloom | Hodgkin lymfoom | Burkitt lymfoom | Acute lymfatische leukemie | Chronische lymfatische leukemie | Lymfoplasmacytisch lymfoom | Acute myeloïde leukemie | Mantelcellymfoom | Chronische myelogene leukemie | Prolymfatische Leukemie | Klein lymfocytisch... en andere voorwaardenVerenigde Staten
Klinische onderzoeken op inotuzumab ozogamicin (CMC-544)
-
Wyeth is now a wholly owned subsidiary of PfizerVoltooid
-
Institute of Hematology & Blood Diseases HospitalNog niet aan het werven
-
PfizerUCB PharmaVoltooidAcute lymfatische leukemieVerenigde Staten
-
PfizerVoltooidVoorlopercel lymfoblastische leukemie-lymfoomVerenigd Koninkrijk
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)BeëindigdTerugkerende acute lymfoblastische leukemie | Refractaire acute lymfoblastische leukemie | CD22 PositiefVerenigde Staten
-
PfizerVoltooid
-
PfizerUCB PharmaVoltooidB-cel lymfoomVerenigde Staten, België, Korea, republiek van, Zwitserland, Frankrijk, Polen, Spanje, Hongkong, Australië, Duitsland, Italië, Nederland, Verenigd Koninkrijk
-
M.D. Anderson Cancer CenterWyeth is now a wholly owned subsidiary of PfizerVoltooidAcute lymfatische leukemieVerenigde Staten
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WervingAcute lymfatische leukemie | B Acute lymfoblastische leukemie | Terugkerende B acute lymfoblastische leukemieVerenigde Staten
-
Cristiana SessaVoltooidB-cel lymfoom refractairZwitserland